Xavier Charmetant

Dr. Xavier Charmetant

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 November 2021 in Kidney International
Verified
Journal Article
Closed access
MEMaxime Espi
Maxime Espi
XCXavier Charmetant
Xavier Charmetant
TBThomas Barba
Thomas Barba
Cyrille MathieuCyrille Mathieu
Cyrille Mathieu
CPCaroline Pelletier
Caroline Pelletier
ISIacobelli Silvia
Iacobelli Silvia

16 March 2022 in Science Translational Medicine
Verified
Journal Article
Open access
XCXavier Charmetant
Xavier Charmetant
MEMaxime Espi
Maxime Espi
Ilies BenotmaneIlies Benotmane
Ilies Benotmane
VBVéronique Barateau
Véronique Barateau
FHFrancoise Heibel
Francoise Heibel
OTOlivier Thaunat
Olivier Thaunat
Transplant recipients, who receive therapeutic immunosuppression to prevent graft rejection, are characterized by high coronavirus disease 2019 (COVID-19)–related mortality and defective response to vaccines. We observed that previous infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), but not the standard two-dose regimen of vaccination, provided protection against symptomatic COVID-19 in kidney transplant recipients. We therefore compared the cellular and humoral immune responses of these two groups of patients. Neutralizing anti–receptor-binding domain (RBD) immunoglobulin G (IgG) antibodies were identified as the primary correlate of protection for transplant recipients. Analysis of virus-specific B and T cell responses suggested that the generation of neutralizing anti-RBD IgG may have depended on cognate T-B cell interactions that took place in germinal center, potentially acting as a limiting checkpoint. High-dose mycophenolate mofetil, an immunosuppressive drug, was associated with fewer antigen-specific B and T follicular helper (T FH ) cells after vaccination; this was not observed in patients recently infected with SARS-CoV-2. Last, we observed that, in two independent prospective cohorts, administration of a third dose of SARS-CoV-2 mRNA vaccine restored neutralizing titers of anti-RBD IgG in about 40% of individuals who had not previously responded to two doses of vaccine. Together, these findings suggest that a third dose of SARS-CoV-2 mRNA vaccine improves the RBD-specific responses of transplant patients treated with immunosuppressive drugs.

21 September 2022 in Science Translational Medicine
Verified
Journal Article
Closed access
XCXavier Charmetant
Xavier Charmetant
CCChien-Chia Chen
Chien-Chia Chen
SHSarah Hamada
Sarah Hamada
DGDavid Goncalves
David Goncalves
CSCarole Saison
Carole Saison
OTOlivier Thaunat
Olivier Thaunat
The generation of antibodies against donor-specific major histocompatibility complex (MHC) antigens, a type of donor-specific antibodies (DSAs), after transplantation requires that recipient’s allospecific B cells receive help from T cells. The current dogma holds that this help is exclusively provided by the recipient’s CD4 + T cells that recognize complexes of recipient’s MHC II molecules and peptides derived from donor-specific MHC alloantigens, a process called indirect allorecognition. Here, we demonstrated that, after allogeneic heart transplantation, CD3ε knockout recipient mice lacking T cells generate a rapid, transient wave of switched alloantibodies, predominantly directed against MHC I molecules. This is due to the presence of donor CD4 + T cells within the graft that recognize intact recipient’s MHC II molecules expressed by B cell receptor–activated allospecific B cells. Indirect evidence suggests that this inverted direct pathway is also operant in patients after transplantation. Resident memory donor CD4 + T cells were observed in perfusion liquids of human renal and lung grafts and acquired B cell helper functions upon in vitro stimulation. Furthermore, T follicular helper cells, specialized in helping B cells, were abundant in mucosa-associated lymphoid tissue of lung and intestinal grafts. In the latter, more graft-derived passenger T cells correlated with the detection of donor T cells in recipient’s circulation; this, in turn, was associated with an early transient anti–MHC I DSA response and worse transplantation outcomes. We conclude that this inverted direct allorecognition is a possible explanation for the early transient anti-MHC DSA responses frequently observed after lung or intestinal transplantations.

14 May 2019 in Clinical Kidney Journal
Verified
Journal Article
Open access
XCXavier Charmetant
Xavier Charmetant
CTCécile Teuma
Cécile Teuma
JLJennifer Lake
Jennifer Lake
FDFrédérique Dijoud
Frédérique Dijoud
VFVincent Frochot
Vincent Frochot
ADAbbas Deeb
Abbas Deeb
The main manifestation of acute interstitial nephritis (AIN) due to immune checkpoint inhibitors is acute kidney injury. We report here a biopsy-proven AIN revealed by tubular acidosis. This case highlights that immune checkpoint inhibitor prescribers must be aware of electrolytic disorders since tubular dysfunction can precede serum creatinine increase and reveal renal toxicity.

3 February 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
XCXavier Charmetant
Xavier Charmetant
MEMaxime Espi
Maxime Espi
TBThomas Barba
Thomas Barba
AOAnne Ovize
Anne Ovize
EMEmmanuel Morelon
Emmanuel Morelon
OTOlivier Thaunat
Olivier Thaunat
Kidney transplant recipients (KTRs) have reduced ability to mount adequate antibody response after two doses of the COVID-19 mRNA vaccine. French health authorities have allowed a third booster dose (D3) for KTRs, but their response is heterogeneous and tools able to discriminate the responders are lacking.

6 September 2022 in Journal of Tissue Engineering
Verified
Journal Article
Open access
SSSophie R Shyfrin
Sophie R Shyfrin
MFMarion Ferren
Marion Ferren
LPLaure Perrin-Cocon
Laure Perrin-Cocon
MEMaxime Espi
Maxime Espi
XCXavier Charmetant
Xavier Charmetant
Cyrille MathieuCyrille Mathieu
Cyrille Mathieu
Kidney pathology is frequently reported in patients hospitalized with COVID-19, the pandemic disease caused by the Severe acute respiratory coronavirus 2 (SARS-CoV-2). However, due to a lack of suitable study models, the events occurring in the kidney during the earliest stages of infection remain unknown. We have developed hamster organotypic kidney cultures (OKCs) to study the early stages of direct renal infection. OKCs maintained key renal structures in their native three-dimensional arrangement. SARS-CoV-2 productively replicated in hamster OKCs, initially targeting endothelial cells and later disseminating into proximal tubules. We observed a delayed interferon response, markers of necroptosis and pyroptosis, and an early repression of pro-inflammatory cytokines transcription followed by a strong later upregulation. While it remains an open question whether an active replication of SARS-CoV-2 takes place in the kidneys of COVID-19 patients with AKI, our model provides new insights into the kinetics of SARS-CoV-2 kidney infection and can serve as a powerful tool for studying kidney infection by other pathogens and testing the renal toxicity of drugs.